Conditions for combining gene therapy with bone marrow transplantation in murine Krabbe disease

Mohammad A Rafi, Paola Luzi, David A Wenger, Mohammad A Rafi, Paola Luzi, David A Wenger

Abstract

Introduction: Krabbe disease (KD) is an autosomal recessive lysosomal disorder caused by mutations in the galactocerebrosidase (GALC) gene. This results in defective myelination in the peripheral and central nervous systems due to low GALC activity. Treatment at this time is limited to hematopoietic stem cell transplantation (HSCT) in pre-symptomatic individuals. While this treatment extends the lives of treated individuals, most have difficulty walking by the end of the first decade due to peripheral neuropathy. Studies in the murine model of KD, twitcher (twi) combining bone marrow transplantation (BMT) with AAVrh10-mGALC showed a great extension of life from 40 days to about 400 days, with some living a full life time. Methods: In order to find the optimum conditions for dosing and timing of this combined treatment, twi mice were injected with five doses of AAVrh10-mGALC at different times after BMT. Survival, as well as GALC expression were monitored along with studies of sciatic nerve myelination and possible liver pathology. Results: Dosing had a pronounced effect on survival and measured GALC activity. There was window of time after BMT to inject the viral vector and see similar results, however delaying both the BMT and the viral injection shortened the lifespans of the treated mice. Lowering the viral dose too much decreased the correction of the sciatic nerve myelination. There was no evidence for hepatic neoplasia. Conclusion: These studies provide the conditions optimum for successfully treating the murine model of KD. There is some flexibility in dosing and timing to obtain a satisfactory outcome. These studies are critical to the planning of a human trial combining the "standard of care", HSCT, with a single iv injection of AAVrh10-GALC.

Keywords: AAVrh10 gene therapy; Bone marrow transplantation; Combined therapy; Krabbe disease; Myelination; Twitcher mice.

© 2020 The Author(s).

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
Fig. 4
Fig. 4
Fig. 5
Fig. 5
Fig. 6
Fig. 6

References

    1. Wenger DA, Rafi MA, Luzi P. Krabbe disease: One Hundred years from the bedside to the bench to the bedside. J Neurosci Res. 2016;94:982–9. doi: 10.1002/jnr.23743.
    1. Wenger DA. Murine, canine and non-human primate models of Krabbe disease. Mol Med Today. 2000;6:449–51.
    1. Yeager AM, Brennan S, Tiffany C, Moser HW, Santos GW. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science. 1984;225:1052–4. doi: 10.1126/science.6382609.
    1. LeVine SM, Pedchenko TV, Bronshteyn IG, Pinson DM. L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice) J Neurosci Res. 2000;60:231–6. doi: 10.1002/(SICI)1097-4547(20000415)60:2<231::AIDJNR12>;2-E.
    1. Wu YP, McMahon EJ, Matsuda J, Suzuki K, Matsushima GK, Suzuki K. Expression of immune-related molecules is downregulated in twitcher mice following bone marrow transplantation. J Neuropathol Exp Neurol. 2001;60:1062–74. doi: 10.1093/jnen/60.11.1062.
    1. Biswas S, LeVine SM. Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr Res. 2002;51:40–7. doi: 10.1203/00006450-200201000-00009.
    1. Rafi MA, Zhi Rao H, Passini MA, Curtis M, Vanier MT, Zaka M. et al. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol Ther. 2005;11:734–44. doi: 10.1016/j.ymthe.2004.12.020.
    1. Lee WC, Tsoi YK, Troendle FJ, DeLucia MW, Ahmed Z, Dicky CA. et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 2007;21:2520–7. doi: 10.1096/fj.06-6169com.
    1. Lin D, Donsante A, Macauley S, Levy B, Vogler C, Sands MS. Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy. Mol Ther. 2007;15:44–52. doi: 10.1038/sj.mt.6300026.
    1. Luzi P, Abraham RM, Rafi MA, Curtis M, Hooper DC, Wenger DA. Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res. 2009;1300:146–58. doi: 10.1016/j.brainres.2009.09.017.
    1. Strazza M, Luddi A, Carbone M, Rafi MA, Costantino-Ceccarini E, Wenger DA. Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Mol Genet Metab. 2009;97:27–34. doi: 10.1016/j.ymgme.2009.01.005.
    1. Reddy AS, Kim JH, Hawkins-Salsbury JA, Macauley SL, Tracy ET, Vogler CA. et al. Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy. J Neurosci. 2011;31:9945–57. doi: 10.1523/JNEUROSCI.1802-11.2011.
    1. Qin EY, Hawkins-Salsbury JA, Jiang X, Reddy AS, Farber NB, Ory DS. et al. Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy. Mol Genet Metab. 2012;107:186–96. doi: 10.1016/j.ymgme.2012.05.021.
    1. Rafi MA, Rao HZ, Luzi P, Curtis MT, Wenger DA. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther. 2012;20:2031–42. doi: 10.1038/mt.2012.153.
    1. Berardi AS, Pannuzzo G, Graziano A, Costantino-Ceccarini E, Piomboni P, Luddi A. Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients. Mol Genet Metab. 2014;112:294–301. doi: 10.1016/j.ymgme.2014.05.009.
    1. Rafi MA, Rao HZ, Luzi P, Luddi A, Curtis MT, Wenger DA. Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features. Mol Genet Metab. 2015;114:459–66. doi: 10.1016/j.ymgme.2014.12.300.
    1. Rafi MA, Rao HZ, Luzi P, Wenger DA. Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice. Mol Ther. 2015;23:1681–90. doi: 10.1038/mt.2015.145.
    1. Hawkins-Salsbury JA, Shea L, Jiang X, Hunter DA, Guzman AM, Reddy AS. et al. Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. J Neurosci. 2015;35:6495–505. doi: 10.1523/JNEUROSCI.4199-14.2015.
    1. Ricca A, Rufo N, Ungari S, Morena F, Martino S, Kulik W. et al. Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy. Hum Mol Genet. 2015;24:3372–89. doi: 10.1093/hmg/ddv086.
    1. Karumuthil-Melethil S, Marshall MS, Heindel C, Jakubauskas B, Bongarzone ER, Gray SJ. Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant. J Neurosci Res. 2016;94:1138–51. doi: 10.1002/jnr.23882.
    1. Marshall MS, Issa Y, Jakubauskas B, Stoskute M, Elackattu V, Marshall JN. et al. Long-Term Improvement of Neurological Signs and Metabolic Dysfunction in a Mouse Model of Krabbe's Disease after Global Gene Therapy. Mol Ther. 2018;26:874–89. doi: 10.1016/j.ymthe.2018.01.009.
    1. Wilkinson FL, Sergijenko A, Langford-Smith KJ, Malinowska M, Wynn RF, Bigger BW. Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Mol Ther. 2013;21:868–76. doi: 10.1038/mt.2013.29.
    1. Chen YQ, Rafi MA, de Gala G, Wenger DA. Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Hum Mol Genet. 1993;2:1841–5. doi: 10.1093/hmg/2.11.1841.
    1. Chen YQ, Wenger DA. Galactocerebrosidase from human urine: purification and partial characterization. Biochim Biophys Acta. 1993;1170:53–61. doi: 10.1016/0005-2760(93)90175-9.
    1. Luzi P, Rafi MA, Wenger DA. Structure and organization of the human galactocerebrosidase (GALC) gene. Genomics. 1995;26:407–9. doi: 10.1016/0888-7543(95)80230-j.
    1. Rafi MA, Fugaro J, Amini S, Luzi P, de Gala G, Victoria T. et al. Retroviral vector-mediated transfer of the galactocerebrosidase (GALC) cDNA leads to overexpression and transfer of GALC activity to neighboring cells. Biochem Mol Med. 1996;58:142–50. doi: 10.1006/bmme.1996.0042.
    1. Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 1968;162:570–2. doi: 10.1126/science.162.3853.570.
    1. Colella P, Ronzitti G, Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol Ther Methods Clin Dev. 2018;8:87–104. doi: 10.1016/j.omtm.2017.11.007.
    1. Gessler DJ, Tai PWL, Li J, Gao G. Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System. Methods Mol Biol. 2019;1950:143–63. doi: 10.1007/978-1-4939-9139-6_8.
    1. Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S. et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005;352:2069–81. doi: 10.1056/NEJMoa042604.
    1. Krivit W, Shapiro EG, Peters C, Wagner JE, Cornu G, Kurtzberg J. et al. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med. 1998;338:1119–26. doi: 10.1056/NEJM199804163381605.
    1. Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study. Neurology. 2017;89:1365–72. doi: 10.1212/WNL.0000000000004418.
    1. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73:3994–4003.
    1. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol. 2001;75:6199–203. doi: 10.1128/JVI.75.13.6199-6203.2001.
    1. Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J Virol. 2001;75:12382–92. doi: 10.1128/JVI.75.24.12382-12392.2001.
    1. Sakai N, Inui K, Tatsumi N, Fukushima H, Nishigaki T, Taniike M. et al. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J Neurochem. 1996;66:1118–24. doi: 10.1046/j.1471-4159.1996.66031118.x.
    1. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
    1. Wenger DA WC. Screening for lysosomal disorders. In: Hommes FA, editor. Techniques in Diagnostic Human Biochemical Genetics. New York, NY: Wiley-Liss; 1991. p. 587-617.
    1. Yamamoto K, Miwa Y, Abe-Suzuki S, Abe S, Kirimura S, Onishi I. et al. Extramedullary hematopoiesis: Elucidating the function of the hematopoietic stem cell niche (Review) Mol Med Rep. 2016;13:587–91. doi: 10.3892/mmr.2015.4621.
    1. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T. et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001;8:1343–6. doi: 10.1038/sj.gt.3301541.
    1. Bell P, Wang L, Lebherz C, Flieder DB, Bove MS, Wu D. et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther. 2005;12:299–306. doi: 10.1016/j.ymthe.2005.03.020.
    1. Buning H, Schmidt M. Adeno-associated Vector Toxicity-To Be or Not to Be? Mol Ther. 2015;23:1673–5. doi: 10.1038/mt.2015.182.
    1. Chandler RJ, LaFave MC, Varshney GK, Burgess SM, Venditti CP. Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for Human Gene Therapy? Mol Ther. 2016;24:198–201. doi: 10.1038/mt.2016.17.
    1. Ichioka T, Kishimoto Y, Brennan S, Santos GW, Yeager AM. Hematopoietic cell transplantation in murine globoid cell leukodystrophy (the twitcher mouse): effects on levels of galactosylceramidase, psychosine, and galactocerebrosides. Proc Natl Acad Sci U S A. 1987;84:4259–63. doi: 10.1073/pnas.84.12.4259.
    1. Gelb MH. Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis Tools. Int J Neonatal Screen. 2018;4 doi: 10.3390/ijns4030023.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren